A Study to Evaluate the Efficacy and Safety of CT-P27 in Acute Uncomplicated Influenza A Infection
Phase 2
Terminated
NCT03511066
| Condition | Influenza A |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Terminated |
|---|
| Enrollment | 228 participants |
|---|
| Interventions | CT-P27 90 mg/kg, CT-P27 45 mg/kg |
|---|
| Start date | Dec 9, 2016 |
|---|
| Completion date | Mar 9, 2018 |
|---|
| Results posted | Oct 31, 2022 |
|---|
Summary
This study is a Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled study evaluating the efficacy and safety of CT-P27 in subjects with acute uncomplicated influenza A infection.
Time to Resolution of Influenza Symptoms and Fever
Twice a day (Morning and Evening) from Day 1 to Day 8 · Days
| CT-P27 90 mg/kg | 3.74 Days |
|---|
| CT-P27 45mg/kg | 3.69 Days |
|---|
| Placebo | 5.72 Days |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.